Answers are grounded in this paper and cite their sources.
A BSTRACT Background: Epilepsy is a common chronic neurological disorder in children, significantly affecting quality of life, cognitive development, and social adaptation. Pharmacoresistance remains a major clinical challenge and occurs in approximately 20%–30% of cases. Aims and Objectives: This study aimed to assess the clinical and epidemiological characteristics of epilepsy in children of the Kazakh population receiving carbamazepine, with particular emphasis on pharmacoresistant forms. Materials and Methods: A prospective–retrospective study included 1198 children with epilepsy in the Aktobe region, where the total pediatric population was 317,754. The prevalence of epilepsy was 0.38%. During the prospective phase, 286 patients underwent clinical and neurological examination, electroencephalography, and neuroimaging evaluation. Results: Males predominated among the patients, accounting for 56.5% of cases. The mean age was 9.85 years, and the mean age at seizure onset was 2.99 years. Pharmacoresistant epilepsy was identified in 38.7% of patients. Focal seizures were observed in 67.5% of cases and were significantly associated with pharmacoresistance ( P = 0.031). Electroencephalographic predictors included hypsarrhythmia, detected in 65.2% of cases, and multiregional abnormalities, detected in 42.9% of cases ( P < 0.05). Structural brain abnormalities were found in 40.9% of patients, particularly tuberous sclerosis complex and porencephaly. Conclusion: Pediatric epilepsy in the Kazakh population is characterized by a high rate of pharmacoresistance. Clinical, electroencephalographic, and neuroimaging features may contribute to early identification of pharmacoresistant epilepsy and optimization of treatment strategies.
No takes yet. Share an insight, caveat, or question.
Dosbolova et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: